A new direct measurement tool suggests that Bisphenol A (BPA)
levels in humans are drastically higher than previous estimates, raising new
alarms about the safety of this endocrine disrupting chemical (EDC). The
findings, published in The Lancet Diabetes & Endocrinology, debunk previous
evidence by the U.S. Food and Drug Administration (FDA) that BPA exposure levels
are safe and call into question previous methods used to measure BPA.
Studies
have traditionally used an indirect process to measure BPA metabolites. This
involves taking a crude enzyme solution made from the Helix pomatia snail to
convert BPA glucuronide and BPA sulfate to free BPA. A liquid
chromatography-mass spectrometry (LC-MS/MS) assay is then used to obtain whole
BPA (free and conjugated) levels in urine.
The LC-MS/MS assay can only
measure BPA—so the levels of conjugated BPA are measured indirectly, Roy Gerona,
PhD, the study’s first author and an assistant professor at the University of
California San Francisco, explained to CLN Stat. “A split sample of the urine is
measured right away for BPA (free or unconjugated BPA). The other split sample
is deconjugated enzymatically then the total BPA is measured by LC-MS/MS. The
conjugated BPA level is derived from the difference between the total BPA and
free BPA,” he said.
Gerona and his colleagues developed a new method that
does not employ enzyme deconjugation. Instead, the LC-MS/MS method directly
measures BPA, BPA glucuronide, and BPA sulfate. “Direct methods provide a tool
to assess the accuracy of the widely used indirect methods,” wrote Gerona and
his associates.
The investigators compared results from their new direct
method versus results from indirect methods used by the Centers for Disease
Control and Prevention and the FDA on synthetic urine spiked with BPA, following
up with 39 human samples. The new direct method found much higher levels of
BPA—exceeding 44 times the average amount reported by the National Health and
Nutrition Examination Survey (NHANES). Disparities between the two methods
increased with increased exposure to BPA.
Gerona hopes the study will bring
attention to current BPA measurement methodology and that other experts and labs
will take notice and assess this circumstance. “BPA is still being measured
indirectly through NHANES, and it’s not the only EDC being measured this way,”
according to Gerona. Gerona spoke on the role of clinical labs in measuring EDCs
in biological samples. “Our hypothesis now is that if this is true for BPA, it
could be true for all the other chemicals that are measured indirectly,” he said
in a statement.
These findings come on the heels of a consensus framework
that identified the key characteristics of EDCs, flagging BPA as a disruptor
that alters hormone distribution or circulating levels of hormones. In addition
to pursuing the research on BPA, Gerona and his team plan to assess other
chemicals that may have been measured incorrectly. These include environmental
phenols such as parabens, benzophenone, triclosan, and phthalates.